Related Experiment Video
Updated: Apr 15, 2026
Inducing Myointimal Hyperplasia Versus Atherosclerosis in Mice: An Introduction of Two Valid Models
Published on: May 14, 2014
Endogenously generated omega-3 fatty acids attenuate vascular inflammation and neointimal hyperplasia by interaction
Xinzhi Li1, Laurel L Ballantyne1, Xinghui Che1
1Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada (X.L., L.L.B., X.C., C.D.F.).
Background:
Omega-3 polyunsaturated fatty acids (ω3 PUFAs) suppress inflammation through activation of free fatty acid receptor 4 (FFAR4), but this pathway has not been explored in the context of cardiovascular disease. We aimed to elucidate the involvement of FFAR4 activation by ω3 PUFAs in the process of vascular inflammation and neointimal hyperplasia in mice.
Methods And Results:
We used mice with disruption of FFAR4 (Ffar4(-/-)), along with a strain that synthesizes high levels of ω3 PUFAs (fat-1) and a group of crossed mice (Ffar4(-/-)/fat-1), to elucidate the role of FFAR4 in vascular dysfunction using acute and chronic thrombosis/vascular remodeling models. The presence of FFAR4 in vascular-associated cells including perivascular adipocytes and macrophages, but not platelets, was demonstrated. ω3 PUFAs endogenously generated in fat-1 mice (n=9), but not in compound Ffar4(-/-)/fat-1 mice (n=9), attenuated femoral arterial thrombosis induced by FeCl3. Neointimal hyperplasia and vascular inflammation in the common carotid artery were significantly curtailed 4 weeks after FeCl3 injury in fat-1 mice (n=6). This included greater luminal diameter and enhanced blood flow, reduced intima:media ratio, and diminished macrophage infiltration in the vasculature and perivascular adipose tissue compared with control mice. These effects were attenuated in the Ffar4(-/-)/fat-1 mice.
Conclusions:
These results indicate that ω3 PUFAs mitigate vascular inflammation, arterial thrombus formation, and neointimal hyperplasia by interaction with FFAR4 in mice. Moreover, the ω3 PUFA-FFAR4 pathway decreases inflammatory responses with dampened macrophage transmigration and infiltration.
Insights
Omega-3 fatty acids reduce vascular inflammation and thrombus formation by activating FFAR4. This pathway is crucial for mitigating neointimal hyperplasia and improving blood flow in mice.
Area of Science:
- Cardiovascular Biology
- Inflammation Research
- Pharmacology
Background:
- Omega-3 polyunsaturated fatty acids (PUFAs) are known to suppress inflammation via free fatty acid receptor 4 (FFAR4).
- The role of this pathway in cardiovascular disease, specifically vascular inflammation and neointimal hyperplasia, remains largely unexplored.
Purpose of the Study:
- To investigate the involvement of FFAR4 activation by omega-3 PUFAs in vascular inflammation and neointimal hyperplasia.
- To elucidate the mechanism by which omega-3 PUFAs exert protective effects in vascular dysfunction.
Main Methods:
- Utilized genetically modified mice: FFAR4 knockout (Ffar4(-/-)), high omega-3 PUFA synthesizing (fat-1), and compound Ffar4(-/-)/fat-1 mice.
- Employed acute and chronic thrombosis and vascular remodeling models (FeCl3 injury).
- Assessed FFAR4 expression in vascular-associated cells and evaluated thrombosis, neointimal hyperplasia, and inflammatory markers.
Main Results:
- FFAR4 was present in vascular-associated cells, including perivascular adipocytes and macrophages, but not platelets.
- Endogenous omega-3 PUFAs in fat-1 mice attenuated arterial thrombosis and reduced neointimal hyperplasia and vascular inflammation post-injury.
- These protective effects were diminished in compound Ffar4(-/-)/fat-1 mice, indicating FFAR4 dependency.
Conclusions:
- Omega-3 PUFAs, through interaction with FFAR4, effectively mitigate vascular inflammation, arterial thrombus formation, and neointimal hyperplasia in a mouse model.
- The omega-3 PUFA-FFAR4 pathway plays a significant role in reducing inflammatory responses by dampening macrophage transmigration and infiltration.
Related Concept Videos
01:26Atherosclerosis III: Management
01:38Inflammation